Product Highlight - Pontevia

16 Mar 2022
Product Highlight - Pontevia
• PONTEVIA is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.1
• The onset of efficacy of galcanezumab is within 1 week in a majority of patients.2
• Galcanezumab 120mg given once monthly was efficacious and well tolerated.3

References:
1. Pontevia Malaysia Approved Prescribing Information, Version 06 Nov 2020.
2. Goadsby PJ, et al. Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. J Neurol Neurosurg Psychiatry 2019;90:939–944.
3. Skljarevski V, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454.


Adverse events should be reported to zpmypv@zuelligpharma.com.
For healthcare professionals only

Related MIMS Drugs

Editor's Recommendations